GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Last update: 06 Mar, 3:50AM

145.14

-3.08 (-2.08%)

Add to watchlist

Previous Close	148.22
Open	146.51
Volume	6,915,056
Avg. Volume (3M)	7,458,168
Market Cap	180,179,779,584

Price / Earnings (TTM)	21.41
Price / Earnings (Forward)	16.69
Price / Sales	6.22
Price / Book	7.98

52 Weeks Range	93.37 (-35%) — 157.29 (8%)
Earnings Date	23 Apr 2026
TTM Dividend Yield	1.63%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Mixed
	Drug Manufacturers - General (Global)	Bullish	Mixed
Stock	Gilead Sciences, Inc.	Bullish	Bullish

AIStockmoo Score

1.2

Analyst Consensus	1.5
Insider Activity	3.0
Price Volatility	-0.5
Technical Moving Averages	2.5
Technical Oscillators	-0.5
Average	1.20

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
GILD	180 B	1.63%	21.41	7.98
AMGN	198 B	2.63%	25.83	23.51
AZN	301 B	0.27%	29.75	6.21
SNY	109 B	4.92%	19.15	1.28
BIIB	26 B	-	16.16	1.53
GRFS	8 B	1.91%	14.00	0.910

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Value
% Held by Insiders	0.10%
% Held by Institutions	89.79%

52 Weeks Range	93.37 (-35%) — 157.29 (8%)
Price Target Range	118.00 (-18%) — 180.00 (24%)
High	180.00 (Jefferies, 24.02%)	Buy
Median	155.00 (6.79%)
Low	118.00 (RBC Capital, -18.70%)	Hold
Average	157.55 (8.55%)
Total	9 Buy, 2 Hold
Avg. Price @ Call	148.12

Firm	Date	Target Price	Call	Price @ Call
Jefferies	10 Mar 2026	180.00 (24.02%)	Buy	148.56
Needham	23 Feb 2026	170.00 (17.13%)	Buy	149.83
Needham	11 Feb 2026	170.00 (17.13%)	Buy	155.80
Barclays	20 Feb 2026	155.00 (6.79%)	Hold	151.40
Cantor Fitzgerald	11 Feb 2026	155.00 (6.79%)	Buy	155.80
RBC Capital	11 Feb 2026	118.00 (-18.70%)	Hold	155.80
Scotiabank	11 Feb 2026	177.00 (21.95%)	Buy	155.80
Truist Securities	11 Feb 2026	152.00 (4.73%)	Buy	155.80
Truist Securities	27 Jan 2026	145.00 (-0.10%)	Buy	140.97
Wells Fargo	11 Feb 2026	165.00 (13.68%)	Buy	155.80
Citigroup	27 Jan 2026	156.00 (7.48%)	Buy	140.97
Citigroup	07 Jan 2026	140.00 (-3.54%)	Buy	124.35
UBS	26 Jan 2026	155.00 (6.79%)	Buy	137.78
UBS	07 Jan 2026	145.00 (-0.10%)	Buy	124.35
Morgan Stanley	13 Jan 2026	150.00 (3.35%)	Buy	121.76
Show more

No data within this time range.

Date	Type	Details
06 Feb 2026	Announcement	FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
27 Jan 2026	Announcement	Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
21 Jan 2026	Announcement	New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
06 Jan 2026	Announcement	OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate
22 Dec 2025	Announcement	Gilead Sciences to Present at Upcoming Investor Conference
22 Dec 2025	Announcement	Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
19 Dec 2025	Announcement	Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
19 Dec 2025	CNBC	Nine of the largest pharma companies ink deals with Trump to lower drug prices
18 Dec 2025	Announcement	Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
15 Dec 2025	Announcement	Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

TTM Dividend Yield	1.63%
5Y Average Dividend Yield	3.38%
Payout Ratio	65.13%
Expected Next Dividend Payment	Mar 2026

Ex Date	Announcement Date	Payment Date	Details
15 Dec 2025	28 Oct 2025	30 Dec 2025	0.79 Cash
15 Sep 2025	29 Jul 2025	29 Sep 2025	0.79 Cash
13 Jun 2025	22 Apr 2025	27 Jun 2025	0.79 Cash
14 Mar 2025	05 Feb 2025	28 Mar 2025	0.79 Cash
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 Cash
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 Cash
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 Cash
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 Cash
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 Cash
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 Cash
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 Cash
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 Cash
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 Cash
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 Cash
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 Cash
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 Cash
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 Cash
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 Cash
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 Cash
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 Cash
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 Cash
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 Cash
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 Cash
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 Cash
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 Cash
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 Cash
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 Cash
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 Cash
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 Cash
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 Cash
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 Cash
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 Cash
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 Cash
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 Cash
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 Cash
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 Cash
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 Cash
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 Cash
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 Cash
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 Cash
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 Cash
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 Cash
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	3.16	4	2.58
2024	3.08	4	3.33
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	20.76%
Operating Margin (TTM)	38.49%
Diluted EPS (TTM)	4.76
Quarterly Revenue Growth (YOY)	-0.30%
Quarterly Earnings Growth (YOY)	24.80%

Total Debt/Equity (MRQ)	130.79%
Current Ratio (MRQ)	1.37
Operating Cash Flow (TTM)	10.37 B
Levered Free Cash Flow (TTM)	9.99 B

Return on Assets (TTM)	12.14%
Return on Equity (TTM)	32.65%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)